Rocket Pharma Posts Q2 Results, Advances Gene Therapy Pipeline with FDA Talks
RCKT sits 43% above its 52-week low of $2.53.
Summary
Rocket Pharmaceuticals reported Q2 2026 financial results and provided pipeline updates. The company highlighted the $180M non-dilutive capital from the priority review voucher sale and safety clearance for the first three Danon disease patients in the pivotal trial. Rocket is engaging with the FDA on next steps for RP-A501 and expects a regulatory update in H2 2026. The PKP2-ACM program also has FDA alignment discussions ongoing, with an update expected in H2 2026. Patient screening has begun for the BAG3-DCM Phase 1 trial, with dosing anticipated in H2 2026. The KRESLADI commercialization strategy is focused on a limited network of treatment centers. No specific Q2 financial figures were disclosed in the headline or article body, limiting immediate trading impact. This follows the positive RP-A501 safety update from August 3, which already moved the stock. The company expects its cash runway to extend into the second quarter of 2028.
At the time of this announcement, RCKT was trading at $3.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $396.4M. The 52-week trading range was $2.53 to $5.45. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: BusinessWire.